How to appeal a CareFirst BCBS endocrine (non-diabetes) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for endocrine (non-diabetes)

Cited policy: BCBS Pharmacy Policy — Crinecerfont (Crenessity)

Classic CAH genotype-confirmed. Adolescents and adults. Glucocorticoid dose minimization goal.

How CareFirst BCBS denies endocrine (non-diabetes) — and how to counter it

Where CareFirst BCBS pushes back: 1) 'Experimental / new drug'; 2) GC dose 'adequate'; 3) Pediatric coverage limitations.

Counter-arguments that hold up: FDA approved Dec 2024 — first new CAH treatment in decades. Cite CAHtalyst Adult + Pediatric trials. Endocrine Society 2018 CAH guidelines endorse glucocorticoid minimization goal. Document supraphysiologic GC dose + adverse effects (Cushingoid features, BMD loss, growth impairment in peds, metabolic syndrome).

What CareFirst BCBS typically denies for endocrine (non-diabetes)

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For endocrine (non-diabetes), expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the endocrine (non-diabetes) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• TRT
• Tepezza (TED)
• Crenessity (CAH)
• Isturisa (Cushing's)
• Recorlev
• Mycapssa

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.